The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited
Abstract
OBJECTIVE— The Diabetes Control and Complications Trial (Diabetes 44:968–983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS— We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS— Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS— A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006) · Diabetes Care · doi:10.2337/dc06-0293 · Cited by 377
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Self-citation
Cited by
Items 101–200 of 555
Risk Factor Variability and Cardiovascular Outcome
Messerli, F. H., Hofstetter, L., Rimoldi, S. F., Rexhaj, E., & Bangalore, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.063 · Cited by 95
Cardoso, C. R. L., Leite, N. C., Dib, E., & Salles, G. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-05159-6 · Cited by 104
Glycemic variability and diabetes retinopathy: A missing link
Hsu, C.-R., Chen, Y., & Sheu, W. H. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.013 · Cited by 86
Diabetic retinopathy and systemic factors
Frank, R. N. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.154388 · Cited by 99
A Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control
Kovatchev, B. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.04.008 · Cited by 80
Plasma metabolomic profiling of proliferative diabetic retinopathy
Zhu, X.-R., Yang, F., Lü, J., Zhang, H., Sun, R., Zhou, J., & Yang, J. (2019) · Nutrition & Metabolism · doi:10.1186/s12986-019-0358-3 · Cited by 79
Orsi, E., Solini, A., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Gruden, G., Morano, S., Nicolucci, A., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13306 · Cited by 77
Self-citationIs diabetes an acquired disorder of reactive glucose metabolites and their intermediates?
Fleming, T. H., Cuny, J., Nawroth, G., Djuric, Z., Humpert, P. M., Zeier, M. G., Bierhaus, A., & Nawroth, P. P. (2012) · Diabetologia · doi:10.1007/s00125-012-2452-1 · Cited by 77
Socio‐economic and ethnic inequalities in diabetes retinal screening
Gulliford, M. C., Dodhia, H., Chamley, M., McCormick, K., Mohamed, M., Naithani, S., & Sivaprasad, S. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02946.x · Cited by 77
Guo, Q., Zang, P., Xu, S.-Y., Song, W., Zhang, Z., Liu, C., Guo, Z., Chen, J., Lu, B., Gu, P., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/5817074 · Cited by 80
Relationship between dyslipidemia and diabetic retinopathy: A systematic review and meta-analysis
Zhou, Y., Wang, C., Shi, K., & Yin, X. (2018) · Medicine · doi:10.1097/md.0000000000012283 · Cited by 79
Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately
Ahola, A. J., Mäkimattila, S., Saraheimo, M., Mikkilä, V., Forsblom, C. M., Freese, R., Groop, P., & on behalf of the FinnDIANE Study Group (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00086.x · Cited by 72
Aschner, P. J., Horton, E., Leiter, L. A., Munro, N. M., Skyler, J. S., & Management*, O. B. O. T. G. P. F. E. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02296.x · Cited by 76
Penno, G., Solini, A., Zoppini, G., Orsi, E., Fondelli, C., Zerbini, G., Morano, S., Cavalot, F. L., Lamacchia, O., Trevisan, R., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-98 · Cited by 75
Self-citationDefinition of intervention points in prediabetes
Ferrannini, E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70175-x · Cited by 72
Monnier, L., & Colette, C. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30003-9 · Cited by 78
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
“A reanalysis of the Diabetes Control and Complications Trial, which initially suggested the risk for microvascular complications may be related to postprandial hyperglycemia, found these results to be an artifact of the statistical models used.(26) Instead, the risk for complications was primarily determined by HbA1c.”
ResultZiegler, D., Behler, M., Schroers-Teuber, M., & Roden, M. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006559 · Cited by 74
Hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53491-0.00023-7 · Cited by 70
Berg, C. A., Butner, J., Wiebe, D. J., Lansing, A. H., Osborn, P. G., King, P. S., Palmer, D. L., & Butler, J. M. (2017) · Developmental Review · doi:10.1016/j.dr.2017.09.001 · Cited by 80
Li, X., Cai, Y., Wang, Y., Shi, Y., Hou, W., Xu, C., Wang, H., Ye, Z., Yao, L.-B., & Zhang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047600 · Cited by 68
“Diabetes-induced hyperglycaemia has been implicated in the development of diabetes-specific pathology [31].”
BackgroundDiabetic Retinopathy: Battling the Global Epidemic
Das, A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21031 · Cited by 68
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1310 · Cited by 60
Leslie, R. D., & Cohen, R. M. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300403 · Cited by 61
Tay, J., Thompson, C. H., & Brinkworth, G. D. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-121214-104422 · Cited by 66
“6% of the variation in retinopathy risk across the entire study cohort was explained by the treatment group alone (133), and only 11% of the difference in retinopathy risk was attributed to HbA1c and diabetes duration.”
BackgroundMaghbooli, Z., Pasalar, P., Keshtkar, A., Farzadfar, F., & Larijani, B. A. (2014) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-13-55 · Cited by 70
“Severity of hyperglycemia, present of hypertension and diabetes duration; are widely recognized as major risk factors for the development of DR [19,20]; however explained approximately 10% of variation in DR [21-23].”
BackgroundIntroduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 64
The Diabetes Control and Complications Trial: the gift that keeps giving
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.179 · Cited by 63
“The DCCT investigators also revisited this subject, and found that the differences in the risk of complications that were originally described between treatment groups with the same HbA 1c levels was probably an artifact of assumptions initially used in the models”
Malhotra, N. A., Greenlee, T. E., Iyer, A. I., Conti, T. F., Chen, A. X., & Singh, R. P. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.03.010 · Cited by 59
Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin
Nathan, D. M., Steffes, M. W., Sun, W., Rynders, G. P., & Lachin, J. M. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.150250 · Cited by 56
Self-citationDysglycaemia, vasculopenia, and the chronic consequences of diabetes
Gerstein, H. C., & Werstuck, G. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70025-1 · Cited by 61
Lachin, J. M., Bebu, I., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc21-1331 · Cited by 59
Self-citationTakao, T., Idé, T., Yanagisawa, H., Kikuchi, M., Kawazu, S., & Matsuyama, Y. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.027 · Cited by 60
Xu, W., Zhu, Y., Yang, X., Deng, H., Yan, J., Lin, S., Yang, H.-Z., Chen, H., & Weng, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.078 · Cited by 54
Do Genomic Factors Play a Role in Diabetic Retinopathy?
Cabrera, A. P., Monickaraj, F., Rangasamy, S., Hobbs, S., McGuire, P. G., & Das, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010216 · Cited by 75
“Other factors, genetic and/or environmental, may explain the remaining 89% of the variation in retinopathy risk [23].”
BackgroundMethodGene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
Wang, J.-H., Ling, D. L., Tu, L., van Wijngaarden, P., Dusting, G. J., & Liu, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.01.003 · Cited by 59
“However, further analysis of data from the entire DCCT cohort suggest that HbA1c levels and duration of diabetes only account for approximately 11% of the variation in risk of DR, suggesting that other components play a role (Lachin et al., 2008).”
Brorsson, A. L., Viklund, G., Örtqvist, E., & Lindholm Olinder, A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12209 · Cited by 52
Ong, J. X., Konopek, N., Fukuyama, H., & Fawzi, A. A. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.06.018 · Cited by 62
Preventing diabetic complications: A primary care perspective
Zimmet, P. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.01.016 · Cited by 51
Liu, Z., Yang, Y., Dong, W., Liu, Q., Wang, R., Pang, J., Xia, X., Zhu, X., Liu, S., Shen, Z., et al. (2019) · Molecules · doi:10.3390/molecules24091776 · Cited by 48
“Sucrase and maltase were obtained from the intestinal brush border of Wistar rats [31].”
New Insights into Treating Early and Advanced Stage Diabetic Retinopathy
Simó, R., & Hernández, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158513 · Cited by 56
Ziemssen, F., Lemmen, K. D., Bertram, B., Hammes, H., & Agostini, H. T. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0315-8 · Cited by 50
Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine
McCall, A. L., Cox, D. J., Brodows, R., Crean, J., Johns, D., & Kovatchev, B. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0107 · Cited by 46
Wang, Y., & Yan, H. (2016) · Scientific Reports · doi:10.1038/srep26909 · Cited by 50
Garcia‐Tirado, J., Lv, D., Corbett, J. P., Colmegna, P. H., & Breton, M. D. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106401 · Cited by 46
The generation of pancreatic β-cell spheroids in a simulated microgravity culture system
Tanaka, H., Tanaka, S., Sekine, K., Kita, S., Okamura, A., Takebe, T., Zheng, Y., Ueno, Y., Tanaka, J., & Taniguchi, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.003 · Cited by 47
Glucose variability and inner retinal sensory neuropathy in persons with type 1 diabetes mellitus
Stem, M. S., Dunbar, G. E., Jackson, G. R., Farsiu, S., Pop‐Busui, R., & Gardner, T. W. (2016) · Eye · doi:10.1038/eye.2016.48 · Cited by 49
Ung, C., Sanchez, A. V., Shen, L., Davoudi, S., Ahmadi, T., Navarro-Gomez, D., Chen, C. J., Hancock, H., Penman, A. D., Hoadley, S., et al. (2017) · Vision Research · doi:10.1016/j.visres.2017.03.007 · Cited by 45
“The Diabetes Control and Complications Trial (DCCT) showed the strongest factors (duration of diabetes and hemoglobin A1c) explained 11% of the risk of developing retinopathy (Lachin et al., 2008).”
BackgroundDeveloping the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Siracusa, R., Impellizzeri, D., Cordaro, M., Gugliandolo, E., Peritore, A. F., Paola, R. D., & Cuzzocrea, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00871 · Cited by 43
Nakanishi, K., & Watanabe, C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1209 · Cited by 50
McCall, A. L., & Kovatchev, B. P. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300102 · Cited by 51
The NIDDK Central Repository at 8 years--Ambition, Revision, Use and Impact
Turner, C. F., Pan, H. H., Silk, G. W., Ardini, M.-A., Bakalov, V., Bryant, S., Cantor, S., Chang, K.-Y., DeLatte, M., Eggers, P., et al. (2011) · Database · doi:10.1093/database/bar043 · Cited by 45
Gurung, R. L., FitzGerald, L. M., Liu, E., McComish, B. J., Kaidonis, G., Ridge, B., Hewitt, A. W., Vote, B. J. T., Verma, N., Craig, J. E., et al. (2023) · International Journal of Retina and Vitreous · doi:10.1186/s40942-023-00453-0 · Cited by 49
Nyiraty, S., Pesei, F., Orosz, A., Coluzzi, S., Vági, O. E., Lengyel, C., Ábrahám, G., Frontoni, S., Kempler, P., & Várkonyi, T. T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00174 · Cited by 46
Physical Activity in Adolescent Females with Type 1 Diabetes
Schweiger, B. M., KLINGENSMITH, G. J., & Snell‐Bergeon, J. K. (2010) · International Journal of Pediatrics · doi:10.1155/2010/328318 · Cited by 45
“This is of important clinical significance since the DCCT [3] and other studies [25] have demonstrated conclusively that improved glycemic control, as assessed by A1c, markedly reduces the development of and progression of microvascular complications of diabetes such as retinopathy, neuropathy, and nephropathy.”
New Diabetes Diagnostic Threshold of Hemoglobin A1c and the 3-Year Incidence of Retinopathy
Tsugawa, Y., Takahashi, O., Meigs, J. B., Davis, R. B., Imamura, F., Fukui, T., Taylor, W. C., & Wee, C. C. (2012) · Diabetes · doi:10.2337/db12-0103 · Cited by 44
Torimoto, K., Okada, Y., Hajime, M., Tanaka, K., & Tanaka, Y. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0017 · Cited by 41
Zhang, X., Zhao, S., Huang, Y., Ma, M., Li, B., Li, C., Zhu, X., Xu, X., Chen, H., Zhang, Y. Z., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032626 · Cited by 47
“8,57 Our study showed a less robust association be-tween diabetes MacroVCs and diabetes MicroVCs in patients with T1D.”
BackgroundEducation, glucose control, and mortality risks among U.S. older adults with diabetes
Dupre, M. E., Silberberg, M., Willis, J. M., & Feinglos, M. N. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.12.013 · Cited by 43
Kilpatrick, E. S. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300405 · Cited by 41
Elsharkawy, M., Elrazzaz, M., Sharafeldeen, A., Alhalabi, M., Khalifa, F., Soliman, A., Elnakib, A., Mahmoud, A., Ghazal, M., El-Daydamony, E., et al. (2022) · Sensors · doi:10.3390/s22093490 · Cited by 38
“According to The Diabetes Control and Complications Trial (DCCT), these factors explain 11% of the risk of developing retinopathy [4].”
MethodGlycemic control in the clinical management of diabetic patients
Mosca, A., Lapolla, A., & Gillery, P. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0594 · Cited by 39
Expressions of Serum lncRNAs in Diabetic Retinopathy – A Potential Diagnostic Tool
Biswas, S., Coyle, A., Chen, S., Gostimir, M., Gonder, J. R., & Chakrabarti, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851967 · Cited by 40
“Furthermore, when comparing between NPDR and PDR patients, no significant differences were observed across age, type of diabetes, BMI, creatinine, HbA1c, and gender distribution.”
BackgroundInfluentialLipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
“[1] Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, DCCT/EDIC Research Group.”
Picconi, F., Flaviani, A. D., Malandrucco, I., Giordani, I., & Frontoni, S. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.03.006 · Cited by 42
Nakanishi, K., & Watanabe, C. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.01.004 · Cited by 36
Glycemic Variability: Can We Bridge the Divide Between Controversies?
Monnier, L., & Colette, C. (2011) · Diabetes Care · doi:10.2337/dc11-0071 · Cited by 46
Mather, K. J., Bebu, I., Baker, C., Cohen, R. M., Crandall, J. P., DeSouza, C., Green, J. B., Kirkman, M. S., Krause-Steinrauf, H., Larkin, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108235 · Cited by 34
Contemporary Management of Patients with Type 1 Diabetes
Mehta, S. N., & Wolfsdorf, J. I. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.002 · Cited by 38
Thomas, A., Schönauer, M., Achermann, F., Schnell, O., Hanefeld, M., Hj, Z., Mastrototaro, J. J., & Heinemann, L. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0119 · Cited by 35
Bogdanov, P. M., Solà-Adell, C., Hernández, C., García‐Ramírez, M., Sampedro, J., Simó‐Servat, O., Valeri, M., Pasquali, C., & Simó, R. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.07.009 · Cited by 35
Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy
Cabrera, A. P., Mankad, R. N., Marek, L., Das, R., Rangasamy, S., Monickaraj, F., & Das, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082712 · Cited by 34
“in risk for retinopathy, and “other factors” may be responsible for the rest 89% of the risk variation among subjects independent of HbA1C levels [79].”
BackgroundElimination of Hypoglycemia From the Lives of People Affected by Diabetes
Cryer, P. (2011) · Diabetes · doi:10.2337/db10-1359 · Cited by 34
“In addition, there are long-term benefits from reducing A1C from higher to lower—albeit still above recommended—levels (16).”
BackgroundKovatchev, B. P. (2012) · Scientifica · doi:10.6064/2012/283821 · Cited by 39
“As noted above, while target HbA1c values of 7% or less result in decreased risk of vascular complications [27, 29, 31, 33], the risk for severe hypoglycemia increases with tightening glycemic control [34, 48].”
BackgroundBjerg, L., Hulmán, Á., Carstensen, B., Charles, M., Jørgensen, M. E., & Witte, D. R. (2018) · Diabetes Care · doi:10.2337/dc18-0679 · Cited by 39
Chen, Y., Zhu, Z., Cheng, W., Bulloch, G., Chen, Y., Liao, H., Li, Y., Liang, X., Huang, W., He, M., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.11.018 · Cited by 31
Debele, G. R., Kanfe, S. G., Weldesenbet, A. B., Ayana, G. M., Jifar, W. W., & Raru, T. B. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s300373 · Cited by 32
Huang, Y., Yue, L., Qiu, J., Gao, M., Liu, S., & Wang, J. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1880-0978 · Cited by 36
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 29
Association of Diabetic Retinopathy With Stroke: A Systematic Review and Meta-Analysis
Hu, K., Jiang, M., Zhou, Q. X., Zeng, W., Lan, X., Gao, Q., Mei, F., Zhao, L., Chen, F., Wu, A., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.626996 · Cited by 33
Cummings, D. M., Larsen, L. C., Doherty, L., Lea, C. S., & Holbert, D. (2011) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2011.04.100186 · Cited by 29
“Active research programs are currently underway to identify new risk factors that may be more strongly and consistently linked to CKD.18 Treatment with ACEIs or ARBs of diabetic patients with confirmed microalbuminuria or proteinuria, even in the absence of hypertension, has been shown to slow progression of CKD.16,19…”
ResultInfluentialChowdhury, S. R., Thomas, R., Dunseath, G. J., Peter, R., Rees, A., North, R. V., Luzio, S. D., & Owens, D. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2203 · Cited by 28
“The UKPDS and DCCT, along with their 10 year follow-up, have demonstrated the benefits of early and sustained improvement in glycaemic control with respect to DR (9, 10).”
MethodInfluentialShikama, M., Sonoda, N., Morimoto, A., Suga, S., Tajima, T., Kozawa, J., Maeda, N., Otsuki, M., Matsuoka, T., Shimomura, I., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13444 · Cited by 28
Okosun, I. S., Annor, F., Dawodu, E. A., & Eriksen, M. P. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2014.04.026 · Cited by 31
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 43
SCHMITT, A. J., Reimer, A., Ehrmann, D., Kulzer, B., Haak, T., & Hermanns, N. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.004 · Cited by 29
Retinal Biomarkers in Diabetic Retinopathy: From Early Detection to Personalized Treatment
Chondrozoumakis, G., Chatzimichail, E., Habra, O., Vounotrypidis, E., Παπάνας, Ν., Gatzioufas, Z., & Panos, G. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041343 · Cited by 34
“Gly-cosylated hemoglobin (HbA1C) is currently the only soluble serum biomarker with clinical use [12,20], while most of the potential soluble biomarkers are in the preclinical stage of evaluation.”
Kähler, P., Grevstad, B., Almdal, T., Gluud, C. N., Wetterslev, J., Vaag, A. A., & Hemmingsen, B. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004806 · Cited by 35
“3 100%/101% ‡ NR Shah et al(101) 12/14 (26) 13.”
Glycemic Variability in Hospitalized Patients: Choosing Metrics While Awaiting the Evidence
Braithwaite, S. S. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0345-9 · Cited by 29
Subclinical lipohypertrophy——Easily ignored complications of insulin therapy
Luo, D., Shi, Y., Zhu, M., Wang, H., Yan, D., Yu, J. Q., Ji, J., Liu, X., Fan, B., Xu, Y., et al. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107806 · Cited by 25
Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT
Zhou, J. J., Koška, J., Bahn, G., & Reaven, P. D. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa941 · Cited by 25
Yoo, J., Cho, E. J., Han, K., Heo, S. S., Kim, B., Shin, D. W., & Yu, S. J. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1654 · Cited by 26
Raman, S., Dai, H. D., DeLurgio, S. A., Williams, D. D., Lind, M., Patton, S. R., Spertus, J. A., Kosiborod, M., & Clements, M. A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12300 · Cited by 27
“Mean glycemic control (HbA1c) is a major determinant of outcomes, but explains only 11% of the population variation in risk (5).”
BackgroundMaple-Brown, L. J., Ye, C., & Retnakaran, R. R. (2012) · Diabetic Medicine · doi:10.1111/dme.12004 · Cited by 25
Prognostic significance of glycemic variability after cardiac surgery
Bansal, B., Carvalho, P., Mehta, Y. B., Yadav, J., Sharma, P., Mithal, A., & Trehan, N. K. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.02.010 · Cited by 30
Diabetic Retinopathy, a Comprehensive Overview on Pathophysiology and Relevant Experimental Models
Gettinger, K., Lee, D., Tomita, Y., Negishi, K., & Kurihara, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209882 · Cited by 36
“Although current treatments emphasize control of blood glucose, recent studies have indicated only about 11% of the variation in DR risk can be attributed to HbA1c levels and the duration of diabetes [24].”
InfluentialA psychosocial risk index for poor glycemic control in children and adolescents with type 1 diabetes
Schwartz, D. D., Axelrad, M. E., & Anderson, B. J. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12084 · Cited by 24
The role of Müller cell glucocorticoid signaling in diabetic retinopathy
Ghaseminejad, F., Kaplan, L., Pfaller, A. M., Hauck, S. M., & Grosche, A. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04521-w · Cited by 27
Glucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 29
Metadata
- Authors
- Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group
- Affiliations
- George Washington University (US)
- Case Western Reserve University (US)
- Harvard University (US)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-04-01
- Volume
- 57
- Issue
- 4
- Pages
- 995-1001
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1992103610
- Cited by
- 555
- References
- 13
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 31 · 2023: 31 · 2022: 34 · 2021: 28 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 31 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 36 · 2012: 25
- FWCI
- 22.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH Clinical Center
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- glycemic exposure, glycemic variability, postprandial hyperglycemia, microvascular complications, diabetic retinopathy progression, HbA1c, tight glycemic control, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Insulin, Male, Reproducibility of Results, Models, Statistical, Cohort Studies, Biomarkers, Disease Progression, Patient Selection, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.